跳至主要内容
临床试验/NL-OMON43833
NL-OMON43833已完成3 期

Clinical effectiveness of standard versus pathogen-reduced buffy coat-derived platelet concentrates in plasma in hemato-oncological patients;Pathogen Reduction Evaluation & Predictive Analytical Rating Score (The PREPAReS Study) - The PREPAReS Study

Sanquin bloedvoorziening0 个研究点目标入组 400 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
400

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • * Age * 18 years.
  • * Expected * 2 platelet transfusion requirements.
  • * Having a hemato-oncological disease

排除标准

  • * Micro-angiopathic thrombocytopenia (TTP, HUS) and ITP
  • * Bleeding > grade 2 at randomization ( after treatment, the patient can be randomized in the study after 2 or more weeks after the last transfusion that was used to stop the bleeding)
  • * Known immunological refractoriness to platelet transfusions.
  • * HLA- and/or HPA-allo immunization and/or clinical relevant auto-antibodies.
  • * Indications to use hyper-concentrated (plasma-reduced) platelet concentrates, i.e. patients with known severe allergic reactions and documented transfusion-associated circulatory overload (TACO)
  • * Pregnancy (or lactating)
  • * Prior treatment with pathogen-reduced blood products
  • * Known allergy to riboflavin or its photoactive products

研究者

发起方
Sanquin bloedvoorziening

相似试验